Vermillion Inc, Fremont, Calif, a molecular diagnostics company, reports that its ovarian cancer protein biomarker panel could help better identify women with ovarian cancer and improve detection of early-stage disease.
A clinical study examining the marker panel for ovarian cancer provided independent validation it can distinguish malignant tumors from benign pelvic masses, and study results demonstrated it could more than double the number of ovarian cancer cases referred to a gynecologic oncologist.
Results of the studies were presented at the Society of Gynecologic Oncologists’39th Annual Meeting on Women’s Cancer in Tampa, Florida.
The company’s diagnostic development program is collaborating with the Johns Hopkins University School of Medicine, Baltimore; The University of Texas MD Anderson Cancer Center; Rigshospitalet, Copenhagen; and the University of Kentucky.
